News for Praxis Precision Medicines, Inc. (PRAX)

**media[646139]**

Praxis Precision Medicine (PRAX) receives a significant update from Oppenheimer as analyst Jay Olson announces a new price target for the company. Olson has set

Analyst Jay Olson from Oppenheimer has initiated coverage on Praxis Precision (PRAX) with an Outperform rating and set a price target of $97. This optimistic vi

On May 7, 2025, Chardan Capital, led by analyst Rudy Li, initiated coverage on Praxis Precision Medicine (PRAX), recommending a "Buy" rating. This marks a signi

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Chardan has begun coverage on Praxis Precision (PRAX) with a Buy rating and set a price target of $80. This optimistic outlook stems from the promising potentia

On May 5, 2025, Wedbush analyst Laura Chico announced an adjustment in the price target for Praxis Precision Medicine (PRAX), a notable player in the biotechnol

Investment firm Baird has increased its price target for Praxis Precision (PRAX) from $73 to $76, while maintaining an Outperform rating. This adjustment follow

Praxis Precision Medicines (PRAX) recently held a virtual event to update investors on its clinical advancements in developmental and epileptic encephalopathies

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. ( PRAX), a clinical-stage biopharmaceutical company translating genetic insights int

On May 5, 2025, Needham's analyst Ami Fadia reiterated a Buy rating for Praxis Precision Medicine (PRAX). The decision comes as Needham maintains its price targ

**media[613234]**

**media[612782]**

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. ( PRAX), a clinical-stage biopharmaceutical company translating genetic insights i

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. ( PRAX), a clinical-stage biopharmaceutical company translating genetic insights i

Whales with a lot of money to spend have taken a noticeably bearish stance on Praxis Precision Medicine. Looking at options history for Praxis Precision Medici...

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Praxis Precision Medicines (PRAX) stock falls amid concerns over success in its late-stage trial for lead asset ulixacaltamide in essential tremor. Read more here.

**media[553406]**